By a News Reporter-Staff News Editor at Women's Health Weekly -- Current study results on Oncology have been published. According to news reporting out of Madrid, Spain, by NewsRx editors, research stated, "In vivo evaluation of tamoxifen (TMX)-loaded folate-targeted nanoparticles prepared from a mixture of disulphide bond reduced bovine serum albumin (BSA-SH) and alginate-cysteine (ALG-CYS) as targeted delivery systems of TMX to tumour tissues. TMX in solution, TMX included into folate-nanoparticles and their non-targeted analogues were intravenously administered to nude mice carrying xenograft MCF-7 tumours."
Our news journalists obtained a quote from the research from Complutense University, "The antitumor activity of these systems was characterized in terms of tumour growth rate, histological and immunohistochemical analysis of tumour tissues and TMX biodistribution. TMX-folate-attached nanoparticles caused tumour remission whereas free TMX or TMX-non-targeted nanoparticles could only stop the tumour development. The histological evaluation of tumour tissues showed that those treated with folate-conjugated systems presented the most quiescent and disorganized structures. Additionally, the lowest concentrations of TMX accumulated in non-targeted organs were also found after administration of the drug using this formulation."
According to the news editors, the research concluded: "This study demonstrated that TMX-loaded folate-targeted systems were capable of reaching tumour sites, so enhancing the in vivo anticancer action of TMX, and allowing a new administration route to be applied and some of the current TMX therapy problems to be overcome."
For more information on this research see: Targeting Tamoxifen to Breast Cancer Xenograft Tumours: Preclinical Efficacy of Folate-Attached Nanoparticles Based on Alginate-Cysteine/Disulphide-Bond-Reduced Albumin. Pharmaceutical Research, 2014;31(5):1264-1274. Pharmaceutical Research can be contacted at: Springer, Plenum Publishers, 233 Spring St, New York, NY 10013, USA. (Springer - www.springer.com; Pharmaceutical Research - www.springerlink.com/content/0724-8741/)
Our news journalists report that additional information may be obtained by contacting A. Martinez, Complutense University Madrid, Dept. of Bioquim & Biol Mol, Fac Med, E-28040 Madrid, Spain. Additional authors for this research include E. Muniz, C. Teijon, I. Iglesias, J.M. Teijon and M.D. Blanco (see also Oncology).
Keywords for this news article include: Spain, Drugs, Madrid, Europe, Therapy, Cysteine, Oncology, Stilbenes, Tamoxifen, Nanoparticle, Breast Cancer, Nanotechnology, Women's Health, Sulfur Amino Acids, Benzene Derivatives, Neutral Amino Acids, Sulfhydryl Compounds, Emerging Technologies, Hormones - Antineoplastics, Selective Estrogen Receptor Modulators
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC